Merck LiteSpark-011: Advanced rCC progression after immunotherapy (Renal Cell Carcinoma)

What is the Purpose of this Study?

If you choose to join this study, you will:
- Be assigned to receive either cabozantinib or belzutifan+lenvatinib (both drugs are pills that you will take each day)
- Have blood draws and give urine samples
- Have imaging tests (CT or MRI, and possibly bone or brain scans, depending on where your cancer has spread)
- Answer questionnaires
What is the Condition Being Studied?
Advanced or Metastatic Renal Cell Carcinoma (RCC) with a Clear Cell Component

Who Can Participate in this Study?

Adults who:

- Are diagnosed with advanced or metastatic RCC

- Have already received an anti-PD-1/L1 therapy

- Have not received more than 2 prior treatments for their cancer

For more information about who can join this study, please contact the study team at

Age Group
Participating Institutions

What is Involved?

We are doing this study to learn if the study drug combination belzutifan+lenvatinib is a safe and effective treatment for renal cell carcinoma. We want to learn what kind of side effects people have when they are taking belzutifan+lenvatinib compared to cabozantinib (an approved treatment for RCC).

Study Details

Full Title
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in
Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
Principal Investigator

Protocol Number

View on